A history of innovative publishing and broad readership appeal

Curated by scientists for scientists, Journal of Experimental Medicine (JEM) provides novel insights into a wide range of biomedical discoveries in the fields of neuroscience, cancer biology, immunology, genetics, and more. And delivers access to them quickly.

Founded in 1896, JEM has emerged as one of the most highly cited life science journals. Long known for its prominence in immunology, in recent years JEM has greatly broadened its scope. Our articles include the latest headlines on topics such as the Zika virus and stem cell research, as well as cutting-edge results in classic paths of study, like inflammation and microbial pathogenesis.

Our scope has expanded, and so has our content, with even more research articles from leading scientists, including Nobel Laureates, Lasker Awardees, and National Medal of Science recipients.

Rapid Publication Increases Value

JEM provides readers timely and newsworthy articles that span multiple disciplines. With broad appeal, daily online publication, and a fully accessible archive dating back over a century, please consider how much your community would gain from JEM.
Who Reads JEM?

JEM publishes original findings on all aspects of disease pathogenesis, and we consider papers reporting novel therapeutic approaches and human studies. The journal’s essential information attracts not only senior researchers, post-docs, and physician-scientists, but also grad and undergrad students. You’ll find JEM readers in many settings:

- Research universities
- Liberal arts colleges
- Medical, dental, and veterinary schools
- Government institutes
- Pharmaceutical companies

Access Made Simple

JEM offers access to both leading-edge discoveries and fully searchable, online PDFs all the way back to 1896. We also offer perpetual access to all content via LOCKSS/CLOCKSS, Portico, PubMed Central (PMC), and Europe PMC.

JEM by the Numbers

<table>
<thead>
<tr>
<th>Category</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pageviews/Year</td>
<td>3.2 Million</td>
</tr>
<tr>
<td>Unique Visitors/Year</td>
<td>870,000+</td>
</tr>
<tr>
<td>Impact Factor (2016)</td>
<td>11.991</td>
</tr>
<tr>
<td>5-Year Impact Factor</td>
<td>13.285</td>
</tr>
<tr>
<td>IF Rank in Medicine, Research and Experimental</td>
<td>5†</td>
</tr>
<tr>
<td>IF Rank in Immunology</td>
<td>7†</td>
</tr>
</tbody>
</table>

Sources: Google Analytics; 2016 Journal Citation Reports® Science Edition; †Among primary research journals.

“Zika virus has oncolytic activity against glioblastoma stem cells,” by Zhu, et al. was listed in Altmetric’s Top 100 most-discussed journal articles of 2017 and has 58,945 views to date.

For More Information

Rockefeller University Press
950 Third Ave., 2nd Fl.
New York, NY 10022
Tel: +1 212.327.8572
Email: subs@rupress.org

JEM is an independent journal published by Rockefeller University Press (RUP), a department of Rockefeller University, a leading biomedical research university dedicated to conducting innovative, high-quality research to improve the understanding of life for the benefit of humanity. RUP also publishes Journal of Cell Biology (JCB) and Journal of General Physiology (JGP).